LMLudovico Mineo

Ludovico Mineo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ludovico Mineo has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of Emotion Dysregulation, Impulsiveness and Rumination in Psychopathology: Evidence from an Italian Sample of Adolescents and Young Adults

    by Sofia Francesca Aprile, Chiara Avanzato, Francesca Alù, Carmen Concerto, Pierfelice Cutrufelli, Ludovico Mineo, Gabriele Privitera, Antonino Petralia, Alessandro Rodolico, Filippo Caraci, et al.

    Background: Adolescence and emerging adulthood are periods of heightened risk for the onset of psychopathology. Emotion dysregulation (ED), impulsiveness, and rumination are transdiagnostic processes implicated across symptom domains, but their relative contributions in clinical youth samples remain unclear. This study examined these three self-regulatory processes simultaneously in first-time help-seeking adolescents and young adults, addressing their differential associations with psychopathological symptom dimensions at an early stage of clinical contact. Methods: We conducted a retrospective observational study with a cross-sectional design in outpatients aged 16–25 years presenting for a first-time psychiatric outpatient consultation at a university hospital in Catania, Italy. Participants completed self-report measures of rumination (RRS), impulsiveness (BIS-11), ED (DERS), and psychopathological symptoms (SCL-90-R). Associations were examined using Spearman’s and partial correlations. Multivariate multiple regression, followed by outcome-specific multiple linear regression models, assessed the relative associations of rumination, ED, and impulsiveness across symptom dimensions. Results: Rumination showed the broadest pattern of unique associations, with FDR-significant associations with eight SCL-90-R domains; the largest coefficient was observed for depression (B = 0.053, 95% CI [0.042, 0.064]). ED was associated with obsessive–compulsive symptoms, depression, anxiety, anger–hostility, and phobic anxiety. Impulsiveness showed more limited associations, remaining significant for anger–hostility and psychoticism. Conclusions: Findings are consistent with a transdiagnostic framework in which rumination and ED relate to multiple symptom dimensions, whereas impulsiveness shows more domain-specific associations. Because the study was cross-sectional and based on self-report measures, these associations should be tested in larger longitudinal and multimethod studies.


  • Open Access

    Antidepressant and Related Neurobiological and Neurophysiological Effects of Add-On Transcranial Direct Current Stimulation in Major Depressive Disorder with Residual Symptoms: A Randomized, Double-Blind Clinical Trial Protocol

    by Carmen Concerto, Fabrizio Bella, Cecilia Chiarenza, Alessandro Rodolico, Antonio Di Francesco, Alessia Ciancio, Stefania Lanzafame, Riccardo Spigarelli, Ludovico Mineo, Antonino Petralia, et al.

    Major depressive disorder (MDD) is a prevalent and disabling condition. Transcranial direct current stimulation (tDCS) may improve symptoms by modulating neuroplastic and inflammatory mechanisms. This randomized, double-blind, placebo-controlled trial will recruit adult outpatients with MDD showing residual symptoms despite at least four weeks of stable SSRI treatment. Participants will be randomized to active or sham add-on tDCS while continuing their antidepressant regimen. The intervention will consist of 15 sessions over 3 weeks, targeting the left dorsolateral prefrontal cortex (anode F3, cathode F4) at 2 mA for 30 min per session. The primary outcome is the reduction of depressive symptoms measured by the Hamilton Depression Rating Scale-17 (HDRS), with remission defined as HDRS-17 ≤ 7. Secondary outcomes include cognitive performance (attention, executive functioning, memory), serum biomarkers (BDNF, VEGF, NGF, NRG1, angiogenin, IGF1, IL-6, TNF-α), cortical excitability assessed by transcranial magnetic stimulation (motor threshold, silent period, intracortical inhibition/facilitation), and cerebral hemodynamics by transcranial Doppler sonography (blood flow velocity, pulsatility, resistivity). Assessments will occur at baseline, post-treatment, and 3- and 6-month follow-ups. This trial aims to evaluate the efficacy of adjunctive tDCS in MDD with residual symptoms and its biological correlates, bridging clinical improvement with electrophysiological and neurovascular mechanisms.


  • Open Access

    Developing STEP‐SE: A Qualitative Usability Study of a Novel Patient‐Reported Outcomes Tool for Managing Side Effects in Shared Decision‐Making for Schizophrenia Spectrum Disorder Care

    by Alessandro Rodolico, Antonio Di Francesco, Pierfelice Cutrufelli, Irene Bighelli, Pasquale Caponnetto, Carmen Concerto, Davide Conti, Rosaria Furnari, Gabriele Leotta, Ludovico Mineo, et al.

    Background: Schizophrenia treatment with antipsychotics often results in side effects that impact adherence and quality of life. Managing these effects remains challenging, as it requires balancing efficacy and tolerability. The Schizophrenia Technological Evaluation of Patient Side Effects (STEP‐SE) app aims to aid side effects monitoring and management through shared decision‐making (SDM).Aim: This study aimed to evaluate the usability of the STEP‐SE app for patients and clinicians in managing antipsychotic side effects.Methods: Sixteen stable outpatients and 14 psychiatrists participated in semi‐structured interviews after using the STEP‐SE app. Questions explored ease of use, information clarity, user needs fulfilment, patient–clinician collaboration, treatment adherence improvement, patient empowerment and clinical utility. Data were analysed thematically.Results: Overall satisfaction with STEP‐SE was high. Both groups found that the tool improved patient involvement, provided reliable information to enhance therapeutic alliance, posed low risks of misunderstanding and had an intuitive interface. Patients felt more motivated and empowered. Clinicians appreciated guideline consistency. Preferences differed regarding data visualization formats.Discussion: STEP‐SE shows potential for aiding SDM on antipsychotic side effects. Patients gained motivation, and clinicians felt reassured. Refinements around mobile access, graphics and features could augment utility. Generalizability is limited given the stable patient sample.Conclusion: Preliminary findings suggest that STEP‐SE effectively engages patients, empowers them and supports clinicians in collaborative side effect management. Further testing with diverse user groups is warranted.Patient or Public Contribution: The current study was designed to gather patient and public feedback for the development of our decision aid tool, STEP‐SE. Participants interacted with the tool's prototype in interactive sessions, providing insights and identifying technical issues. Their feedback was crucial for enhancing the tool, with each suggestion and bug report carefully considered for future iterations. The participants’ contributions were key in optimizing STEP‐SE's features and ensuring its relevance and reliability. We thank all who shared their time and perspectives, significantly shaping the tool's user‐centred design.


  • Open Access

    Exploring Patient Empowerment in Major Depressive Disorder: Correlations of Trust, Active Role in Shared Decision-Making, and Symptomatology in a Sample of Italian Patients

    by Alessandro Rodolico, Pierfelice Cutrufelli, Giuliana Maccarone, Gabriele Avincola, Carmen Concerto, Alfio Luca Cunsolo, Antonio Di Francesco, Rosaria Furnari, Ludovico Mineo, Federico Salerno, et al.

    Background/Objectives: Empowerment in medicine and psychiatry involves patients gaining control over health-related decisions, improving treatment adherence, outcomes, and satisfaction. This concept is especially significant in psychiatric care due to the complex challenges of mental health conditions, including stigma and impairment of emotional and cognitive functioning. We aim to investigate the correlations between patient trust, decision-making involvement, symptom severity, and perceived empowerment among individuals with Major Depression. Methods: Patients with Major Depressive Disorder were recruited in the “Policlinico G. Rodolico” psychiatry outpatient clinic from November 2022 to June 2023. Inclusion criteria: ages 18–65, ability to consent, stable condition, psychiatric medication history, and recent consultation. Exclusion criteria: psychotic features, bipolar disorder, substance abuse, high suicide risk, and severe comorbidities. Measures included the User Scale for Measuring Empowerment in Mental Health Services (SESM), Trust in Oncologist Scale (TiOS), Clinical Decision-Making Style for Patients (CDMS-P), and Hamilton Depression Rating Scale (HAM-D). Analysis used Kendall’s Tau correlation and Two-One-Sided Tests procedure. Results: Seventy-three patients completed the study. No relationship was found between decision-making involvement and perceived empowerment (τ = −0.0625; p = 0.448), or between trust in psychiatrists and empowerment (τ = 0.0747; p = 0.364). An inverse correlation existed between patient involvement in therapy management and trust (τ = −0.2505; p = 0.002). Depression severity inversely correlated with empowerment (τ = −0.2762; p = <.001), but not with trust or decision-making involvement. Conclusions: The lack of significant correlations suggests that decision-making involvement and trust alone may not suffice to enhance empowerment. Trust may encourage patient passivity, while skepticism might drive active involvement. Higher empowerment is associated with less depressive symptoms, highlighting its potential connection with patient outcomes.


  • Open Access

    Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy

    by Alessandro Rodolico, Sofia Francesca Aprile, Pierfelice Cutrufelli, Gabriele Privitera, Sabrina Castellano, Carmen Concerto, Rosaria Furnari, Claudia Savia Guerrera, Ludovico Mineo, Giuseppe Alessio Platania, et al.

    Background Patients undergoing antipsychotic treatment for psychiatric disorders may experience challenges in functioning, either stemming from the severity of the illness or from the tolerability issues of prescribed medications. Objectives The aims of this cross-sectional study are to investigate the impact of adverse effects of antipsychotic drugs on patients’ daily life functioning, comparing oral and long-acting injectable (LAI) antipsychotics, and further dividing antipsychotics by receptor-binding profiles based on recently defined data-driven taxonomy. Methods This study involved patients with schizophrenia and bipolar spectrum disorders taking oral or LAI antipsychotics. Disability and functioning levels were assessed using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS), and the adverse effects of medications were evaluated using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and its subscales. Results The total sample consisted of 126 participants with a diagnosis of schizophrenia-spectrum or bipolar disorder, and included 54 males and 72 females ranging from 18 to 78 years of age (mean 45.1, standard deviation 14); 78 patients were taking oral antipsychotics and 48 were taking LAI antipsychotics, with subcategories of muscarinic (31), adrenergic/low dopamine (25), serotonergic/dopaminergic (23), dopaminergic (1), LAI muscarinic (15), LAI adrenergic (6), and LAI serotonergic/dopaminergic (25). The UKU total score for adverse effects showed significant correlations with WHODAS total score (ρ = 0.475; p < 0.001). Compared with oral antipsychotics, LAIs showed significantly lower scores in psychological (p = 0.014), autonomic (p = 0.008), other (p = 0.004), and sexual adverse effects (p = 0.008), as well as the UKU total score (p = 0.002). The Kruskal–Wallis test showed a significant difference in adverse effects between LAI and oral muscarinic subgroups, with LAIs having lower scores compared with antipsychotics binding to muscarinic receptors (p = 0.043). Conclusion These findings indicate clinically relevant differences in adverse effects among formulations, warranting further investigation for future observational studies.


  • Transcranial Magnetic Stimulation (TMS) for the treatment of amphetamine and amphetamine-type stimulants (ATS) addiction – A systematic review and meta-analysis

    by Carmen Concerto, Cecilia Chiarenza, Antonio Di Francesco, Stefania Lanzafame, Ludovico Mineo, Antimo Natale, Pasquale Caponnetto, Riccardo Spigarelli, Antonio Trovato, Alessandro Rodolico, et al.

    INPLASY202410030 Transcranial Magnetic Stimulation (TMS) for the treatment of amphetamine and amphetamine-type stimulants (ATS) addiction – A systematic review and meta-analysis Keywords: Amphetami…

  • Open Access

    Mental Pain Correlates with Mind Wandering, Self-Reflection, and Insight in Individuals with Psychotic Disorders: A Cross-Sectional Study

    by Alessandro Rodolico, Pierfelice Cutrufelli, Natascia Brondino, Pasquale Caponnetto, Gaetano Catania, Carmen Concerto, Laura Fusar-Poli, Ludovico Mineo, Serena Sturiale, Maria Salvina Signorelli, et al.

    Understanding the cognitive processes that contribute to mental pain in individuals with psychotic disorders is important for refining therapeutic strategies and improving patient outcomes. This study investigated the potential relationship between mental pain, mind wandering, and self-reflection and insight in individuals diagnosed with psychotic disorders. We included individuals diagnosed with a ‘schizophrenia spectrum disorder’ according to DSM-5 criteria. Patients in the study were between 18 and 65 years old, clinically stable, and able to provide informed consent. A total of 34 participants, comprising 25 males and 9 females with an average age of 41.5 years (SD 11.5) were evaluated. The Psychache Scale (PAS), the Mind Wandering Deliberate and Spontaneous Scale (MWDS), and the Self-Reflection and Insight Scale (SRIS) were administered. Statistical analyses involved Spearman’s rho correlations, controlled for potential confounders with partial correlations, and mediation and moderation analyses to understand the indirect effects of MWDS and SRIS on PAS and their potential interplay. Key findings revealed direct correlations between PAS and MWDS and inverse correlations between PAS and SRIS. The mediation effects on the relationship between the predictors and PAS ranged from 9.22% to 49.8%. The largest statistically significant mediation effect was observed with the SRIS-I subscale, suggesting that the self-reflection and insight component may play a role in the impact of mind wandering on mental pain. No evidence was found to suggest that any of the variables could function as relationship moderators for PAS. The results underscore the likely benefits of interventions aimed at reducing mind wandering and enhancing self-reflection in psychotic patients (e.g., metacognitive therapy, mindfulness). Further research will be essential to elucidate the underlying mechanisms.


  • Open Access

    Exploring Personal Recovery in Schizophrenia: The Role of Mentalization

    by Carmen Concerto, Alessandro Rodolico, Ludovico Mineo, Alessia Ciancio, Leonardo Marano, Carla Benedicta Romano, Elisa Vita Scavo, Riccardo Spigarelli, Laura Fusar-Poli, Rosaria Furnari, et al.

    Recovery is a broadly debated concept in the field of psychiatry research and in schizophrenia. Our study aims to understand the correlation between personal recovery from schizophrenia and factors such as mentalization, disability, quality of life, and antipsychotic side effects; Methods: Participants with schizophrenia (according to DSM-5 criteria) were consecutively recruited from the Psychiatry Unit of the University of Catania, Italy. Participants were assessed with the Recovery Assessment Scale (RAS), the Multidimensional Mentalizing Questionnaire (MMQ), the brief version of the WHO Disability Assessment Schedule (WHO-DAS), the EuroQoL-5 dimensions-5 levels, the Insight Orientation Scale (IOS) and the Glasgow Antipsychotic Side Effect Scale (GASS); Results: 81 patients were included. Our findings showed a positive correlation between RAS total scores and MMQ scores, especially in “good mentalizing” subdomains. IOS scores also had a positive association with RAS and MMQ scores. In contrast, poor mentalizing abilities negatively correlated with WHO-DAS 2.0 scores. While antipsychotic side effects influenced functioning, they did not impact perceived recovery. Conclusions: The study’s results identified potential predictors of personal recovery from schizophrenia. These findings could contribute to creating tailored interventions to facilitate the recovery process.


  • Open Access

    Challenging the Pleiotropic Effects of Repetitive Transcranial Magnetic Stimulation in Geriatric Depression: A Multimodal Case Series Study

    by Vincenzo G. Nicoletti, Francesco Fisicaro, Eugenio Aguglia, Rita Bella, Damiano Calcagno, Mariagiovanna Cantone, Carmen Concerto, Raffaele Ferri, Ludovico Mineo, Giovanni Pennisi, et al.

    Background: Although the antidepressant potential of repetitive transcranial magnetic stimulation (rTMS), the pleiotropic effects in geriatric depression (GD) are poorly investigated. We tested rTMS on depression, cognitive performance, growth/neurotrophic factors, cerebral blood flow (CBF) to transcranial Doppler sonography (TCD), and motor-evoked potentials (MEPs) to TMS in GD. Methods: In this case series study, six drug-resistant subjects (median age 68.0 years) underwent MEPs at baseline and after 3 weeks of 10 Hz rTMS on the left dorsolateral prefrontal cortex. The percentage change of serum nerve growth factor, vascular endothelial growth factor, brain-derived growth factor, insulin-like growth factor-1, and angiogenin was obtained. Assessments were performed at baseline, and at the end of rTMS; psychocognitive tests were also repeated after 1, 3, and 6 months. Results: Chronic cerebrovascular disease was evident in five patients. No adverse/undesirable effect was reported. An improvement in mood was observed after rTMS but not at follow-up. Electrophysiological data to TMS remained unchanged, except for an increase in the right median MEP amplitude. TCD and neurotrophic/growth factors did not change. Conclusions: We were unable to detect a relevant impact of high-frequency rTMS on mood, cognition, cortical microcircuits, neurotrophic/growth factors, and CBF. Cerebrovascular disease and exposure to multiple pharmacological treatments might have contributed.


  • Open Access

    A Systematic Review on the Effect of Nutraceuticals on Antidepressant-Induced Sexual Dysfunctions: From Basic Principles to Clinical Applications

    by Carmen Concerto, Alessandro Rodolico, Valeria Meo, Donatella Chiappetta, Marina Bonelli, Ludovico Mineo, Giulia Saitta, Sebastiano Stuto, Maria Salvina Signorelli, Antonino Petralia, et al.

    Sexual dysfunctions are common side effects reported by patients during antidepressant treatment. When they occur, patients often discontinue psychopharmacological therapy, with a negative impact on the underlying psychiatric disease. Recently, great attention has been paid to the use of nutraceuticals in the management of psychiatric disorders, although a systematic review on their effects as a treatment option for antidepressant-induced sexual dysfunctions (AISD) is lacking. Here, we conducted a systematic search in the following databases: MEDLINE (through PubMed), EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, and Web of Science. We searched eligible studies among parallel or crossover randomized controlled trials (RCTs) in adult populations. After this process, a total of 10 articles that evaluated the effect of six different nutraceuticals versus placebo were included: Maca Root, S-adenosyl-L-methionine (SAMe), Rosa Damascena, Ginkgo Biloba, Saffron, and Yohimbine. Overall, a high dose of Maca Root and the use of SAMe or Saffron may improve AISD. Additionally, the administration of Rosa Damascena seemed to be more effective in men than in women, whereas no evidence of effects emerged for Gingko Biloba and Yohimbine. Given the mixed results still available, future RCTs should consider larger samples and confounding factors, such as depressive status and individual vulnerability.